GL1X · GenesisL1 explorer

Research workbench

Serendipitous discovery of aryl boronic acids as beta-lactamase inhibitors

Analyse Serendipitous discovery of aryl boronic acids as beta-lactamase inhibitors in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6UQT
Type
protein
Length
363 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Beta-lactamase
EC
3.5.2.6
UniProt
Q541D8
Ligands
QFS, CL
Pockets
3 · best druggability 0.61

Structure

x-ray diffraction · 1 distinct chain · 43% helix, 22% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABeta-lactamase (EC 3.5.2.6)protein36343% helix, 22% strandQ541D8

Ligands and binding sites

  • QFS · 2-hydroxyethyl hydrogen (3-methoxyphenyl)boronate · ligand · chains A
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13140.610.7941QFS, CL
2620.330.7716empty
3630.320.7516empty

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 6UQT · Serendipitous Discovery of Aryl Boronic Acids as beta-Lactamase Inhibitors · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.